SEHK:2591Biotechs
Guangzhou Innogen (SEHK:2591) Stock Price Sinks As Losses Keep Funding Risks Alive
Guangzhou Innogen Pharmaceutical Group closed at HK$4.02 today, capping a heavy slide over the past month as investors reacted to another loss making set of numbers. The headline this half is not the revenue line; it is the size of the loss relative to a still early stage commercial base.
For H1 2026 the company generated C¥78.218 million of revenue but booked a net loss of C¥115.46 million and a basic loss per share of C¥0.25. The short term pain is clear. The real question now is how the...